FNCH vs. MGNX, TCRX, CLYM, CLLS, XBIT, SRZN, JSPR, PLRX, ZURA, and JMAC
Should you be buying Finch Therapeutics Group stock or one of its competitors? The main competitors of Finch Therapeutics Group include MacroGenics (MGNX), TScan Therapeutics (TCRX), Climb Bio (CLYM), Cellectis (CLLS), XBiotech (XBIT), Surrozen (SRZN), Jasper Therapeutics (JSPR), Pliant Therapeutics (PLRX), Zura Bio (ZURA), and Maxpro Capital Acquisition (JMAC). These companies are all part of the "pharmaceutical products" industry.
Finch Therapeutics Group vs. Its Competitors
Finch Therapeutics Group (NASDAQ:FNCH) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.
In the previous week, MacroGenics had 4 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 4 mentions for MacroGenics and 0 mentions for Finch Therapeutics Group. MacroGenics' average media sentiment score of 0.03 beat Finch Therapeutics Group's score of 0.00 indicating that MacroGenics is being referred to more favorably in the news media.
21.8% of Finch Therapeutics Group shares are held by institutional investors. Comparatively, 96.9% of MacroGenics shares are held by institutional investors. 44.9% of Finch Therapeutics Group shares are held by company insiders. Comparatively, 13.0% of MacroGenics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
MacroGenics has a consensus target price of $5.71, suggesting a potential upside of 296.83%. Given MacroGenics' stronger consensus rating and higher possible upside, analysts clearly believe MacroGenics is more favorable than Finch Therapeutics Group.
MacroGenics has higher revenue and earnings than Finch Therapeutics Group. MacroGenics is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks.
Finch Therapeutics Group has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Comparatively, MacroGenics has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500.
Finch Therapeutics Group has a net margin of 0.00% compared to MacroGenics' net margin of -36.23%. MacroGenics' return on equity of -59.84% beat Finch Therapeutics Group's return on equity.
Summary
MacroGenics beats Finch Therapeutics Group on 13 of the 17 factors compared between the two stocks.
Get Finch Therapeutics Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for FNCH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding FNCH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Finch Therapeutics Group Competitors List
Related Companies and Tools
This page (NASDAQ:FNCH) was last updated on 7/3/2025 by MarketBeat.com Staff
